Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.

Abstract: The present invention is directed to methods for filling a container wherein the filled container has no headspace. The present invention is further directed to methods for stabilizing an aqueous drug substance solution by filling a container with the aqueous drug substance solution wherein the filled container has no headspace. The present invention is further directed to methods for detecting headspace in a container.

Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Abstract: Flexible catheters adapted to be inserted into a body to deliver high-voltage, fast (e.g., microsecond, sub-microsecond, nanosecond, picosecond, etc.) electrical energy to target tissue may include a plurality of conductive layers, that may be coaxial. These catheters and method of using them to treat tissue are configured to reduce or avoid arcing.

Abstract: A microfluidic device can include a microfluidic circuit that comprises an inlet port, a reagent-containing chamber configured to receive fluid from the inlet port, a non-aqueous-liquid-containing reservoir configured to receive liquid from the chamber, and a droplet-generating region configured to receive and produce droplets of liquid from the reservoir. The circuit can also include first and second valves or frangible members. The first valve or frangible member can have closed position in which fluid is prevented from entering or exiting the chamber therethrough and an open position in which fluid is permitted to enter or exit the chamber therethrough. The second valve or frangible member can have a closed position in which fluid is prevented from flowing between the chamber and the reservoir therethrough and an open position in which fluid is permitted to flow between the chamber and the reservoir therethrough.

Abstract: The present invention encompasses methods of cancer immunotherapy, and particularly methods of allogeneic cellular immunotherapy, using particular lymphodepletion regimens in combination with particular populations of chimeric antigen receptor T cells expressing anti CD19 CAR PBCAR0191, anti CD20 CAR PBCAR20A or anti BCMA CAR PBCAR269A.

Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to previously described HBV meganucleases. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.

Abstract: Materials and methods for improving the shelf-life of cannabinoids are described. For example, methods of improving the stability of cannabinoids during storage by applying one or more exogenous terpenes, terpenoids, or blend thereof to a cannabinoid-containing product, and packaging configured to stabilize a cannabinoid-containing product by preserving the applied one or more terpenes, terpenoids, or blend thereof are provided.

Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.

Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.

Abstract: One type of tissue-based assay, the companion diagnostic (“CDx”) allows for the identification of individuals within a larger patient population who are more likely to respond to a therapy. The CDx paradigm typically applies to drugs that target a specific gene product or biologic pathway involving a gene product of interest. It is possible, especially for popular therapeutic targets, for multiple drugs and multiple associated CDx to be developed for a single gene product or biologic pathway involving the gene product. Currently, each of these similar CDx must be applied to identify the best therapy. The present invention can determine the outcome of one CDx using an image of a tissue section used for another CDx. Using a single tissue section and a single CDx, it becomes possible to obtain the outcome of multiple, related CDx.

Abstract: Disclosed is a method of isolating extracellular vesicles and identifying membrane proteins therefrom. The method includes providing human plasma and/or serum; separating lipoproteins and extracellular vesicles from the human plasma and/or serum by a density gradient preparation, collecting the extracellular vesicles from the separated lipoproteins and extracellular vesicles; isolating and purifying the collected extracellular vesicles by using size exclusion chromatography; treating the isolated and purified extracellular vesicles with an aqueous solution to obtain membranes of the extracellular vesicles, wherein the aqueous solution has a pH in a range of 9 to 14; adding salt in a concentration range between 0.5-2.0M to the aqueous solution; isolating the membranes from the treated extracellular vesicles and identifying proteins on the isolated membranes by employing mass spectrometry.

Abstract: The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present disclosure relates to modified extracellular vesicles, e.g., exosomes, comprising an antisense oligonucleotide (ASO), which is capable of reducing and/or inhibiting expression of KRAS mRNA and/or KRAS protein. ASOs that can be used with the modified extracellular vesicles are also disclosed. Also provided herein are methods for using the exosomes and ASOs to treat and/or prevent diseases, such as cancer.

Abstract: The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.

Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.